NCT06876662PHASE4Recruiting

A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma

Eli Lilly and Company

Start Date

5/20/2025

Completion Date

12/1/2032

Summary

Study J2N-MC-JZ01 (JZ01) is an individual-study appendix (ISA) under master protocol J2N-MC-JZNY, and represents participants from the completed originator study, clinical study LOXO-BTK-18001/J2N-OX-JZNA. Participants in the originator study will have the opportunity to continue their assigned study intervention or continue their follow-up visits by transitioning to this study. This study will evaluate the long-term safety and efficacy of pirtobrutinib.

Eligibility Criteria

Age Range: 18 years to No maximum

Inclusion Criteria: * Are currently enrolled and active in the originator study, LOXO-BTK-18001. A participant is considered active in the study if they are: * receiving study intervention * in the short-term follow-up period, or * in the long-term follow-up period Exclusion Criteria: * Were a participant in the Phase 1b cohort of Study LOXO-BTK-18001

Interventions

DRUG

Pirtobrutinib

Interested in This Trial?

Contact the trial locations directly using the information below to learn more about enrollment.

Expressing interest lets you review the study and consent before we connect you with the research site.

Conditions

Chronic Lymphocytic LeukemiaNon-Hodgkin Lymphoma

Locations

Sylvester Comprehensive Cancer Center

Miami, Florida 33136-1002

United States

Florida Cancer Specialists

Sarasota, Florida 34232-6422

United States

The Emory Clinic

Atlanta, Georgia 30322-1013

United States

Northwestern University

Chicago, Illinois 60611-3013

United States

Dana-Farber Cancer Institute

Boston, Massachusetts 02115

United States

Mayo Clinic- Minnesota

Rochester, Minnesota 55905

United States

University Of Nebraska Medical Center

Omaha, Nebraska 69198

United States

Cayuga Cancer Center

Ithaca, New York 14850

United States

Northwell Health

Lake Success, New York 11042-1118

United States

Memorial Sloan-Kettering Cancer Center (MSKCC) - New York

New York, New York 10065-6007

United States

Memorial Sloan-Kettering Cancer Center (MSKCC) - New York

New York, New York 10065-6007

United States

Duke University Medical Center

Durham, North Carolina 27710-4000

United States

Ohio State University Comprehensive Cancer Center

Columbus, Ohio 43210-1063

United States

University of Pennsylvania Hospital

Philadelphia, Pennsylvania 19104

United States

Tennessee Oncology

Nashville, Tennessee 37203-2659

United States

University of Texas MD Anderson Cancer Center

Houston, Texas 77030-4000

United States

Swedish Cancer Institute

Seattle, Washington 98104-3588

United States

Medical College of Wisconsin

Milwaukee, Wisconsin 53226-3548

United States

Flinders Medical Centre

Adelaide, 5042

Australia

Peter MacCallum Cancer Centre

Melbourne, 3000

Australia

Linear Clinical Research

Victoria, 3000

Australia

CHU de Nantes - Hotel Dieu

Nantes, 44093

France

IRCCS-AOU di Bologna-Policlinico S.Orsola-Malpighi

Bologna, 40138

Italy

Ospedale San Raffaele

Milan, 20132

Italy

Nagoya Medical Center

Aichi-Ken, 4600001

Japan

National Cancer Center Hospital

Cho-ku, 104-0045

Japan

National Hospital Organization Kyushu Cancer Center

Fukuoka, 811-1395

Japan

Tokai University Hospital- Isehara Campus

Isehara, 259-1193

Japan

Tohoku University Hospital

Miyagi-Ken, 9808574

Japan

Hokkaido University Hospital

Sapporo, 060-8648

Japan

Pratia MCM Krakow

Krakow, 30727

Poland

Instytut Hermatologii I Transfuzjologii

Warsaw, 02-776

Poland

Seoul National University Hospital

Seoul, 03080

South Korea

St James's University Hospital

Leeds, LS9 7TF

United Kingdom

Churchill Hospital

Oxford, OX3 7LE

United Kingdom

Derriford Hospital

Plymouth, PL6 8DH

United Kingdom